Simple Summary The treatment of advanced and metastatic non-small cell lung cancer
(NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics …

Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …

Historically, patients with advanced stage non‐small cell lung cancer (NSCLC) were treated
with chemotherapy alone, but a therapeutic plateau has been reached. Advances in the …

Abstract Treatment outcomes in advanced or metastatic non-small-cell lung cancer (NSCLC)
remain unsatisfactory, with low long-term survival rates. Palliative chemotherapy offers a …

Precision oncology comprises the set of strategies that aim to design the best cancer
treatment based on tumor biology. A recognized subset of patients with non‐small cell lung …

The discovery that a number of aberrant tumorigenic processes and signal transduction
pathways are mediated by druggable protein kinases has led to a revolutionary change in …

Non-small-cell lung cancer (NSCLC) remains a significant global health challenge and the
leading cause of cancer-related mortality. The traditional 'one-size-fits-all'treatment …

Introduction Several targetable genetic alterations have been identified in non-small cell
lung cancers (NSCLC) and drugs targeting these alterations have been approved for the …

Targeted therapies have changed the landscape of treatments for non-small cell lung cancer
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring …

Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have
predominantly involved the development of therapies directed at molecular targets such as …